Date: 2016-04-19
Type of information: Nomination
Compound:
Company: Melinta Therapeutics (USA - CT)
Therapeutic area: Infectious diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On April 19, 2016, Melinta Therapeutics announced that Eugene Sun has been appointed Melinta’s Chief Executive Officer and member of the Board of Directors, making permanent the role he has filled in an interim capacity since September 2015. Prior to joining Melinta in 2013, Dr. Sun held senior positions at Abbott Laboratories, most recently as Corporate Vice President, Global Pharmaceutical Clinical Development. During his 17-year tenure at Abbott, Dr. Sun led the development and worldwide regulatory approval of the landmark HIV protease inhibitor Kaletra® and oversaw the development and approval of multiple indications for Humira®. He also had responsibility for the anti-infective development portfolio that included compounds in the quinolone, cephalosporin, macrolide and ketolide classes.
- From 2001 to 2007, Dr. Sun served on the FDA Antiviral Drugs Advisory Committee, a panel of independent infectious disease experts. After earning a medical degree from New York University School of Medicine, Dr. Sun completed an internship and residency in internal medicine, and a fellowship in infectious diseases, at the University of California, San Francisco. During his fellowship, Dr. Sun received a National Research Service Award and a Physician Scientist Award from the NIH.
Financial terms:
Latest news:
Is general: Yes
